Equities

Bioxytran Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BIXT:QBB

Bioxytran Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.0428
  • Today's Change0.003 / 6.47%
  • Shares traded76.17k
  • 1 Year change-42.70%
  • Beta2.3783
Data delayed at least 15 minutes, as of Mar 04 2026 20:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

  • Revenue in USD (TTM)0.00
  • Net income in USD-2.11m
  • Incorporated2008
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galera Therapeutics Inc0.00-8.99m3.40m3.00---------0.1302-0.13020.00-1.940.00----0.00-129.27-96.94-145.04-116.42------------34.30------67.91------
Oragenics Inc0.00-10.90m3.46m3.00--0.3482-----17.15-17.150.002.380.00----0.00-121.78-113.47-168.95-126.49-------34,218.60---14.920.0386---100.00--48.84------
Geovax Labs Inc3.35m-25.31m3.54m17.00--0.385--1.05-49.15-49.155.864.130.3759--12.25197,268.20-283.68-128.86-377.44-172.81-----754.69-1,385.19----0.00----27.453.75--22.10--
National Graphite Corp0.00-1.97m3.55m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
Acurx Pharmaceuticals Inc0.00-9.17m3.77m4.00--0.7326-----8.54-8.540.002.020.00----0.00-151.72-158.12-291.07-208.61------------0.00------3.26------
Hcw Biologics Inc422.03k-22.21m3.80m36.00------9.00-13.96-13.960.2716-0.80380.0162--1.2411,723.06-46.35-53.89---66.1020.00---2,855.77-545.79---42.261.45---9.68---20.12---29.10--
Matinas BioPharma Holdings Inc0.00-16.87m3.87m3.00--0.5513-----3.30-3.300.001.090.00----0.00-111.43-49.82-126.56-54.00-------2,545.33----0.0025---100.00---5.71------
Bioxytran Inc0.00-2.11m3.98m2.00---------0.0235-0.02350.00-0.03260.00-------1,340.44-1,468.56---------------1.99--------47.08------
Galmed Pharmaceuticals Ltd0.00-8.70m4.02m3.00--0.1752-----3.60-3.600.003.490.00----0.00-40.91-55.02-46.34-64.19------------0.00-------8.75------
CTT Pharmaceutical Holdings Inc0.00-1.67m4.04m0.00--2.02-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Weed Inc0.00-755.25k4.04m2.00---------0.0058-0.00580.00-0.00380.00----0.00-133.78-117.17---371.94-----------22.55---------1,518.25------
Decoy Therapeutics Inc0.00-5.00m4.21m2.00--0.1468-----39.19-39.190.004.500.00----0.00-100.54-73.17-139.55-84.56-------987.44----0.00------55.55------
Indaptus Therapeutics Inc0.00-16.87m4.22m7.00--0.6702-----31.67-31.670.002.810.00----0.00-223.71-56.08-317.86-68.84-----------13.740.00------2.60------
ENDRA Life Sciences Inc0.00-8.01m4.49m21.00--17.68-----13.35-13.350.000.21780.00----0.00-154.83-132.71-183.46-155.93--------1.31--0.00-------14.39---18.17--
BioRestorative Therapies Inc383.40k-12.67m4.50m11.00--0.7578--11.74-1.48-1.480.04470.27660.0379--4.3034,854.55-125.35-149.02-207.73-188.7193.34---3,304.77-11,837.37----0.00--175.0325.2713.81--24.41--
Revelation Biosciences Inc0.00-14.87m4.58m8.00--0.2199-----62.09-62.090.005.590.00----0.00-97.93-135.98-124.73-249.31------------0.00------1.15------
Data as of Mar 04 2026. Currency figures normalised to Bioxytran Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.